ATHX Athersys, Inc.

+0  (0%)
Previous Close 1.50
Open 1.51
Price To book 11.63
Market Cap 164.70M
Shares 109,803,000
Volume 757,118
Short Ratio 3.64
Av. Daily Volume 1,644,170

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released mid April 2015. Endpoints not met. Phase 3 MASTERS-2 trial to be initiated under SPA in 2017.
Ischemic stroke
Phase 2 enrolment but reported May 2016 that enrolment is slower than expected
Acute myocardial infarction

Latest News

  1. Athersys to Host First Quarter Financial Results Call
  2. Can the Rally in Athersys (ATHX) Shares Continue?
  3. Here's What Might Be Pushing Up Shares of Athersys, Inc. Today
  4. Tonix Pharmaceuticals and Athersys Advance as FDA Clinical Trials Move Forward
  5. Is the Options Market Predicting a Spike in Athersys (ATHX) Stock?
  6. Athersys (ATHX) Stock Rallies as William Blair Initiates Coverage
  7. Athersys to Present at Needham Healthcare Conference on April 4
  8. ETFs with exposure to Athersys, Inc. : March 27, 2017
  9. Athersys, Inc. :ATHX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  10. Two New Publications Highlight the Potential for MultiStem® Treatment of Ischemic Stroke
  11. Athersys, Inc. :ATHX-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017
  12. Edited Transcript of ATHX earnings conference call or presentation 9-Mar-17 9:30pm GMT
  13. Athersys Reports Financial Results for Fourth Quarter, Full Year 2016
  14. Overview of MultiStem® Clinical Trial in Japan Presentation at International Stroke Conference 2017
  15. Athersys to Host Year-End 2016 Financial Results Call
  16. Athersys Announces Closing of Public Offering of Common Stock
  17. Athersys, Inc. (ATHX) Down, Maybe An Opportunity?
  18. Athersys Launches $20M Public Stock Offering
  19. Athersys Announces Pricing of Public Offering of Common Stock